KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Total Liabilities: 2009-2024

Historic Total Liabilities for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $8.4 billion.

  • Regeneron Pharmaceuticals' Total Liabilities rose 13.50% to $9.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 billion, marking a year-over-year increase of 13.50%. This contributed to the annual value of $8.4 billion for FY2024, which is 18.27% up from last year.
  • As of FY2024, Regeneron Pharmaceuticals' Total Liabilities stood at $8.4 billion, which was up 18.27% from $7.1 billion recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Total Liabilities ranged from a high of $8.4 billion in FY2024 and a low of $6.1 billion during FY2020.
  • In the last 3 years, Regeneron Pharmaceuticals' Total Liabilities had a median value of $7.1 billion in 2023 and averaged $7.4 billion.
  • Its Total Liabilities has fluctuated over the past 5 years, first soared by 65.20% in 2020, then decreased by 1.73% in 2022.
  • Regeneron Pharmaceuticals' Total Liabilities (Yearly) stood at $6.1 billion in 2020, then rose by 8.60% to $6.7 billion in 2021, then decreased by 1.73% to $6.6 billion in 2022, then grew by 8.50% to $7.1 billion in 2023, then grew by 18.27% to $8.4 billion in 2024.